HC Wainwright Rates Absci (ABSI) buy, $16 Price Target
HC Wainwright maintains its buy rating on Absci Corporation with a $16 price target, a 39.86% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Absci Corporation ($ABSI) "buy" with a $16 price target on June 25, 2026.
Since the rating, $ABSI is up 13.8% after 1 week, down 25.9% after 1 month and down 19.2% to date (from the $10.21 close on Jun 25, 2026).
ABSI
Absci Corporation
Key Points
- HC Wainwright reiterated its buy rating on Absci Corporation (ABSI) with a $16 price target on June 25, 2026.
- HC Wainwright's $16 price target implies 39.86% upside from Absci Corporation's ($ABSI) current $11.44 share price.
- Shares of Absci Corporation traded at $9.64 on Thursday with a market cap of approximately $1.31 billion.
- Absci Corporation, a biotech firm, has seen insider buying and multiple analysts maintaining buy ratings.
Get $ABSI trade alerts by text
We text you when insiders, Congress or big funds trade $ABSI. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Absci Corporation alert may contain errors. Disclosures
On June 25, 2026, HC Wainwright reiterated its buy rating on Absci Corporation (NasdaqGS: ABSI), maintaining a price target of $16. Analyst Swayampakula Ramakanth continues to see potential in the biotechnology company.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Absci Corporation Stock Up 18.5%
Shares of NasdaqGS:ABSI traded near $9.64 on Thursday. Absci Corporation has a market capitalization of about $1.31 billion and a beta of 2.457, indicating higher volatility compared to the market. The stock has a 52-week low of $2.24 and a high of $8.57, with a 50-day moving average of $5.29 and a 200-day moving average of $3.71. The company holds a strong current ratio of 6.589, suggesting good liquidity.
$ABSI price target
Absci Corporation daily closes and this analyst's $16 target. Not advice.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. maintained its buy rating on Absci Corporation with a $16 price target. Just a day earlier, Needham reiterated its buy rating with an $11 target, while BTIG maintained a buy rating at $13. Guggenheim also maintained a buy rating on June 15, 2026, with a $15 target. Overall, Absci Corporation has a strong buy consensus with a mean price target of $9.61 among 10 analyst opinions.
Insider Buying and Selling at Absci Corporation
Several insiders have shown confidence in Absci Corporation by purchasing shares on June 4, 2026. Mary Szela bought 33,200 shares, followed by another purchase of 8,400 shares. Karen McGinnis also acquired 10,100 shares and later an additional 39,800 shares. Menelas Pangalos purchased 39,800 shares as well. These transactions were not part of any pre-planned trading program.
Other Institutional Activity in Absci Corporation
FMR LLC slightly increased its holdings by 168,995 shares, reaching 22,550,997 shares valued at about $67.65 million. ARK Investment Management LLC added 1,175,370 shares, boosting its position by 9.4% to 13,726,169 shares worth approximately $41.18 million. BlackRock, Inc. trimmed its stake by 78,238 shares, now holding 11,255,194 shares valued at around $33.77 million. Meanwhile, State Street Corp significantly increased its position by 1,333,981 shares, a 22.3% rise, reaching 7,324,858 shares worth about $21.97 million. Vanguard Capital Management LLC opened a new position with 5,886,640 shares valued at roughly $17.66 million.
About Absci Corporation
Absci Corporation is a biotechnology company based in Vancouver, Washington. Founded in 2011, it focuses on developing antibody therapeutics. The company has several preclinical development programs targeting conditions like inflammatory bowel disease, androgenic alopecia, and oncology. Absci collaborates with partners like PrecisionLife and Memorial Sloan Kettering Cancer Center for research. Led by CEO Sean McClain, the company employs about 140 people.
Bottom Line
HC Wainwright's reiterated buy rating and $16 price target reflect ongoing confidence in Absci Corporation's potential in the biotech sector. Investors should note that these ratings are based on past performance and strategic partnerships. Institutional activity and insider buying further highlight the interest in Absci's growth prospects.
Related Filing Alerts
Source: HC Wainwright's rating change on $ABSI (Jun 25, 2026). Written by software, not financial advice. How we make alerts